2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2745

Prevalence of Vasculitides As Extraintestinal Manifestation of Inflammatory Bowel Disease (IBD)
Abstract Number: 2778

Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions
Abstract Number: 2068

Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout
Abstract Number: 1612

Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort
Abstract Number: 2103

Problems in the Diagnosis of Familial Mediterranean Fever in Turkey
Abstract Number: 2313

Procalcitonin Differentiates Infection from Active Disease in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 197

Process Evaluation of the Making It Work Program, an Online Program to Help People with Inflammatory Arthritis Remain Employed
Abstract Number: 80

Production and Characterization of Human Interferon-Epsilon and Interferon-Kappa to Investigate Their Potential Role in Lupus
Abstract Number: 1780

Prognostic Factors in Patients with Granulomatosis with Polyangiitis Requiring Hospitalization- a 10 Year Nationwide Analysis
Abstract Number: 2164

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
Abstract Number: 554

Prognostic Significance of Double Positive Anti Ro/SS-a and La/SS-B Antibodies in Patients with Primary Sjogren’s Syndrome: Prospective Salivary Gland Ultrasound Study
Abstract Number: 820

Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
Abstract Number: 732

Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Abstract Number: 593

Progression of Structural Damage on MRI in Patients with Axial Spondyloarthritis Is Limited: The 5 –Year Results in the DESIR Cohort
Abstract Number: 1660

Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].